Investor Presentation Full Year 2021
83
Investor presentation Full year 2021
CVD presence has been expanded with the Heartseed
collaboration and Prothena ATTR amyloidosis acquisition
Novo Nordisk CVD ambition:
Company
New partnerships and acquisitions to support ambition
Type of agreement
Key asset
Heartseed Inc.
Treatment scope
At least one product
launched between
2024-2028 targeting
atherosclerotic
cardiovascular disease
or heart failure
Exclusive worldwide
collaboration and
license agreement
HS-001
(a stem-cell based
therapy)
Heart failure
Prothena
Corporation plc
Acquisition of
Prothena's ATTR
amyloidosis
programme
PRX004
(an anti-amyloid
immunotherapy)
Novo NordiskⓇ
Expected timing
Heartseed expects
to initiate a phase
1/2 trial in Japan in
H2 2021
ATTR-CM (a rare
heart disease)
Phase 2 expected
to initiate in 2022
followed by a
phase 3 CVOT
Clinical assets:
Ziltivekimab Oral PCSK9i
Other CVD activities
Ongoing major CVOTS:
SELECT
SOUL
FLOW
FOCUS
Note: ATTR-CM Transthyretin Amyloid Cardiomyopathy; CVOT: Cardiovascular Outcome Trial; CVD: Cardiovascular Disease. The partnership and acquisition, respectively, were announced in Q2 2021View entire presentation